Last reviewed · How we verify
Trizivir
At a glance
| Generic name | Trizivir |
|---|---|
| Also known as | abacavir, abacavir sulfate, lamivudine, zidovudine, TZV |
| Sponsor | St. Luke's-Roosevelt Hospital Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV (PHASE2)
- Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV (PHASE2)
- Study of Options for Second-Line Effective Combination Therapy (SELECT) (PHASE3)
- Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults (PHASE4)
- Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
- A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV (PHASE4)
- Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure (PHASE4)
- Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |